SeaStar Medical Holding Corporation
ICUAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | maintain | Buy | May 14, 2026 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.95| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.91 | $-0.97 | $615.0K | $486.5K |
| May 13, 2026 | $-0.90 | $-0.73 | $495.0K | $437.5K |
| Mar 25, 2026 | $-0.80 | $-0.97 | $420.0K | $222.5K |
| Nov 13, 2025 | $-1.30 | $-1.50 | $183.0K | $250.0K |
| Aug 13, 2025 | $-1.80 | $-4.30 | $338.0K | $200.0K |
| May 14, 2025 | $-4.40 | $-5.20 | $293.0K | $150.0K |
| Mar 27, 2025 | $-9.00 | $-8.90 | $67.0K | $150.0K |
| Nov 13, 2024 | $-11.00 | $-11.30 | $68.0K | $75.0K |
News
SAN CLEMENTE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 2026 Jefferies Global Healthcare Conference being held in London, November 15-18, 2026.
ICU Medical NASDAQ: ICUI reported third-quarter revenue of $556 million and said it expects full-year adjusted earnings to finish toward the high end of its existing guidance, as growth in infusion products and improved margins offset a decline in Vital Care.
DENVER, Nov. 04, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Wednesday, November 11, 2026, and host a webcast and conference call to discuss its financial results and business progress.
Stellantis N.V. sustained a $26.3B net loss for 2025, forcing deep cost cuts and a strategic overhaul. The restructuring plan centers on five core brands, with non-core brands facing cuts, closures, or divestitures. STLA's Value Creation Program targets €6B in structural cost reductions by 2028, with 40% by 2027.
DENVER, Nov. 03, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has determined that the QUELIMMUNE Pediatric SAVE Surveillance Registry (SAVE Registry) has fulfilled the post-approval study requirem…
New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital discharge versus comparator cohort No device-related adverse events (AEs) occurred in patients treated with QUELIMMUNE DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatmen…
SAN CLEMENTE, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2026 earnings release and conference call.
Award recognizes Dr. Chung's extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support
Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (F…
DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, today announced the entry into definitive agreements on October 2, 2026, for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 854,002 shares of SeaStar Medical's common stock, originally issued i…
DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, t…
New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ® (SCD-PED) therapy Universal codes establish a framework to enable billing for future potential SCD indications that require renal replacement therapy DENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss o…
Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE ® , an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI)
Prestigious honor recognizes Dr. Humes' pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE ® for critically ill pediatric patients with acute kidney injury (AKI)
DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City.
Quoin Pharmaceuticals releases a new NETHERTON NOW video featuring Laura Wright-Sexton, MD, who first met her daughter Aminah as a patient in the ICU.
SAN CLEMENTE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference on September 9-10, 2026 Company management will attend the Wells Fargo 21st Annual Healthcare Conference, held at the Encore Boston Harbor in Boston, MA, participating in one-on-one meetings on Wednesday, Sept…
SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript
Added 3 top-rated children's hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025